From the Journals

E-cigarette usage has changed

Publish date: May 15, 2018
By
Richard Franki

 

FROM JAMA

Adults were more likely to try e-cigarettes in 2016 than they were in 2014, but they were less likely to use them regularly, according to a study published online on May 15 by JAMA.

The prevalence of ever use of e-cigarettes among adults aged 18 years and older rose significantly from 12.6% in 2014 to 15.3% in 2016, while the prevalence of current use (defined as use every day or some days) decreased significantly from 3.7% to 3.2% over that same period, suggesting “that some individuals are trying but not continuing use of e-cigarettes,” Wei Bao, MD, PhD, and his associates said in a research letter.

Prevalence of e-cigarette use in adults, 2014-2016
The patterns of increased ever use and decreased current use held for most age-, gender-, and race/ethnicity-related subgroups, although “current use of e-cigarettes declined among current smokers but increased among former smokers. This pattern may reflect e-cigarette use as adults are transitioning from current to former smokers, but further investigation is warranted,” wrote Dr. Bao of the University of Iowa College of Public Health, Iowa City, and his associates.

None of the investigators reported any conflicts of interest.

SOURCE: Bao W et al. JAMA. 2018 May 15;319(19):2039-41.

Recommended Reading

VIDEO: Revised guidelines raise lung cancer screening age ceiling
MDedge Family Medicine
Young e-cigarette users graduating to the real thing
MDedge Family Medicine
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Family Medicine
States judged on smoking cessation services
MDedge Family Medicine
States show large disparities in lung cancer mortality
MDedge Family Medicine
FDA wants data on role of flavored tobacco products in youth initiation
MDedge Family Medicine
Bisphosphonate use linked with lower risk of lung cancer for never-smokers
MDedge Family Medicine
EAGLES: Smoking cessation therapy did not up cardiovascular risk
MDedge Family Medicine
Nivolumab shows promise in early-stage resectable NSCLC
MDedge Family Medicine
MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Family Medicine